Itch and pain are two distinct sensory modalities elicited by noxious and pruritic stimuli, respectively. The cellular and electrophysiological characteristics of itch and pain are very similar; thus discerning the mechanical difference between these two sensory modalities has long been elusive. Recent advances in this field have revealed various neuronal receptors responsible for itch and pain signal transduction and transmission. These studies have identified a distinct sub-population of sensory neurons responsible for itch signal transduction. In addition, itch and pain information conveyed to the spinal cord are processed and regulated by distinct spinal cord neurons. Although both itch and pain senses are required for our daily lives, chronic and hyper-sensation of itch and pain results in a debilitating disease state. Studies have now begun to elucidate mechanisms for the sensitization of pain and itch and also to unravel counter-regulatory mechanisms between itch and pain at the spinal cord level. Interestingly, toll-like receptors (TLRs), an innate immune receptor, has been implicated in the central sensitization of both pain and itch. In this review, we will briefly provide an overview of the molecular mechanisms of itch and pain. Additionally, we will discuss the recently uncovered role of TLRs in itch and pain sensation.
Introduction
Itch and pain are two distinct sensory modalities that we experience in our daily lives. Itch is defined as an "unpleasant sensation that elicits the desire to scratch," and pain is an "unpleasant sensory and emotional experience associated with actual or potential tissue damage" [1] . Although their definitions are distinct, they share many similarities. It is believed that both sensory modalities are evolved as protective responses; pain is to evade from the harmful environment and itch is to remove irritants from the body. They utilize similar neurons and neural circuits to transduce and transmit sensory signals. Both C-and A-fibers are involved in itch and pain signal transmission via the spinothalamic tract [2, 3] . Many dorsal root ganglia (DRG) and spinal neurons respond to both itch and pain stimuli. It is not unusual that both senses are co-transmitted and concomitantly perceived; stimulant of one sense often triggers the other sense.
Although both itch and pain sensory modalities are indispensable for the well-being of humans, chronic-and hyper-sensation of these senses lead to debilitating pathological conditions. During pain hypersensitive conditions such as inflammation due to infection or nerve damage, normal noxious stimuli are perceived at a greater intensity (hyperalgesia), and innocuous stimuli elicit pain (allodynia) [4] . Likewise, in certain conditions, normal pruritic stimuli elicit enhanced itch senses (hyperknesis) and non-pruritic stimuli are perceived as itch senses (alloknesis) [5] .Although the mechanisms of hypersensitivity of these sensory modalities have not been completely REVIEW elucidated, studies so far indicate that both alteration in the sensory neurons (peripheral sensitization) and plastic changes at the level of spinal cord or above (central sensitizations) are involved.
However, there are also many differences between itch and pain. As obvious in their definition, pain elicits a withdrawal response while itch elicits a scratch response. In addition, unlike a pain sensation, an itch sensation is perceived only at the body surface [1] . What is more interesting is that itch and pain often counter-regulate each other. For example, noxious stimuli at the periphery of the pruritic site alleviate ongoing itch sensations. Conversely, inhibition of chronic pain by using certain analgesic medicine (e.g. morphine) often induces a pruritic sensation [6] . These observations indicate that itch and pain signals may cross-talk with each other during sensory transmission and somehow suppress the activation of the other, of which the mechanisms have not been clearly elucidated.
Studies of the molecular mechanisms of itch and pain have uncovered various sensory neuronal membrane receptors responding to noxious/pruritic stimuli that are involved in sensory signal transduction. These include members of the transient receptor potential (TRP) channel family, P2X and P2Y receptors, and members of the G-protein coupled receptor (GPCR) family. The functions and mechanisms of these receptors in pain and itch sensations have been previously discussed in several review papers [3, 4, 7] and thus will not be discussed in depth in this review. Recently, toll-like receptors (TLRs) have emerged as novel receptors regulating both pain and itch [8, 9] . TLRs have been known as innate immune receptors and thus little attention has been paid to their role in sensory transmission. However, the roles of TLR in the sensitization of pain and itch have been proposed in recent studies. In this review, I will briefly overview the molecular mechanisms of itch and pain signal transduction and transmission, and discuss the newly revealed and unexpected role of TLRs in itch and pain.
Peripheral mechanisms of itch and pain
Like any other sensory modalities, noxious and pruritic stimuli are detected and transduced to electrical signals by sensory neurons. The sensory neurons conveying pain and itch signals are called nociceptors and pruriceptors, respectively. The sensory neuronal cells located in either the DRG or trigeminal ganglia innervate peripheral organs (including skin) and the spinal cord/medullary dorsal horn, thereby conveying peripheral sensory stimuli encoded in electrical signals to the central nervous system (CNS).
Electrophysiological studies over the past several decades have revealed that pain is transmitted by two classes of sensory nociceptors. Nociceptors of medium-diameter myelinated Aδafferent fibers transmit well-localized acute and sharp pain. Meanwhile, nociceptors of small-diameter non-myelinated C fibers encode poorly localized, delayed and dull pain [10, 11] . The nociceptive C fibers are further divided into peptidergic C fibers that contain peptide neurotransmitters such as substance P (SP) and calcitonin gene-related peptide (CGRP) and non-peptidergic C fibers that are positive for IB4 and P2X3 [12] . Different classes of nociceptors project to anatomically distinct areas of the spinal cord. The Aδ nociceptors project axons to the dorsal horn lamina I and V. The peptidergic C fibers project to lamina I and the outer area of lamina II, while non-peptidergic C fibers project to the inner area of lamina II. The pain information delivered to the dorsal horn is processed by other sensory inputs and inputs from local interneurons and then transmitted to the brain via projection neurons [4] . Studies using molecular biology techniques and with genetically modified mice have identified receptors for the noxious stimuli expressed on nociceptors. For example, screening for the capsaicin receptor has identified a non-selective cation channel responding to noxious heat called the transient receptor potential V1 (TRPV1) in sensory neurons [13] . In the absence of TRPV1, mice do not properly respond to noxious heat [14, 15] . In addition, these knockout mice are also refractory to tissue injury-induced thermal hyperalgesia [14, 15] . This indicates that the TRPV1 channel is used to transduce sensory signals of both noxious heat and inflammatory chemical stimuli. Upon depletion of TRPV1-lineage sensory neurons in TRPV1-DTA mice [16] , such mice failed to respond to noxious heat and chemical mediators. However, these mice were also insensitive to a histamine-induced itch response. These data indicate that TRPV1-expressing sensory neurons not only function as nociceptors but also play a role in sensing itch.
In contrast to nociceptors, the cellular identity of pruriceptors has long been elusive. It was originally thought that itch is a sub-modality of pain. According to this view, itch is perceived when the intensity of noxious stimuli is too weak to induce pain (intensity theory). However, it was soon proven that increasing itch intensity still induced itch, but not pain. Likewise, weakening a pain signal does not transform to an itch sensation [17, 18] , which is an argument against this theory. To the contrary, a study by Schmelz et al., demonstrated the existence of histamine-responsive sensory neurons in C-fiber that are distinct from conventional nociceptive neurons [19] . Similarly, histamine-responding spinal cord lamina I spinothalamic (STT) neurons insensitive to mechanical or thermal stimuli were identified, which suggests that a unique subset of STT neurons mediate itch transmission [20] . These two studies suggest a new possibility that the itch signal is conveyed by distinct sensory neurons and neural circuits independent of the pain signal (labeled-line theory). Since then, great efforts have been made to identify itch-specific sensory neurons and recent studies with genetically modified mice have greatly extended current knowledge on putative itch-specific neurons.
Histamine is the most well-known pruritogen and initial studies have focused on characterizing histamine-responding (histaminergic) sensory neurons. There are four subtypes of histamine receptors, namely H1R1 to 4 that are members of the GPCR family. Among them H1R1, 3, and 4 are detected in skin-innervating sensory neurons [21, 22] . In humans, histamine-induced itch reactions are almost completely suppressed by a H1R1 inhibitor [23] , whereas, in mice, H1R4 contributes to the itch signal as well [24] . Histamine treatment on H1R1-positive sensory neurons triggers intracellular calcium signals and action potentials [25] . The H1R1-dependent intracellular calcium signal is abolished in PLCβ3 knockout mice, indicating that H1R1 utilizes Gq/PLCβ3 as downstream signaling pathways. Histamine-induced itch is also dependent on TRPV1 [25] . Taken together, these studies demonstrate that H1R1/TRPV1-positive sensory neurons are pruriceptors for histaminergic itch.
Notably, many chronic pruritic disorders such as atopic dermatitis are refractory to anti-histamine drug treatments, suggesting that other non-histaminergic itch mediators are involved [26] . For atopic dermatitis, tryptase has been proposed to trigger the itch sensation via activating protease-activating receptor 2 (PAR2), a member of the GPCR family [27] . However, a more recent study argues that PAR2 contributes to atopic dermatitis by inducing thymic stromal lymphopoietin (TSLP) release from keratinocytes [28] . TSLP, in turn, activates a subset of TRPA1-positive skin-innervating neurons to elicit itch. PARs are implicated in the signaling by other pruritogens. Mucunain, a pruritogenic component from cowhage seedpod, triggers an itch sensation via PAR2 and 4 on sensory neurons [29] . More recently, cathepsin S has been found to induce itch, which is also dependent on PAR2 and 4 [30] .
Studies to identify the receptors for other non-histaminergic pruritogens have revealed that several members of the Mas-related G protein coupled receptor (Mrgprs) family (orphan GPCRs) play important roles. For example, chloroquine (CQ), an anti-malaria drug inducing severe non-histaminergic itch as a side effect, binds to MrgprA3 on a sub-set of TRPV1-positive sensory neurons [31] . In addition, MrgprC11 and MrgprD serve as receptors for bovine adrenal medulla 8-2 (BAM8-22) and β-alanine, respectively [9, 31] . Once introduced to human skin, both BAM8-22 and β-alanine induce severe non-histaminergic itch [31, 32] . What is interesting is that both MrgprA3 and MrgprC11 trigger intracellular calcium signals and action potentials through TRPA1 and not TRPV1 activation [33] , indicating a distinct activation mechanism compared to histamine-induced itch signal transduction. MrgprA3 and MrgprC11 are mostly co-expressed in small diameter sensory neurons [31] . Furthermore, these neurons also respond to histamine. Therefore, the MrgprA3-positive sub-population of DRG sensory neurons express MrgprC11, H1R, TRPV1, and TRPA1, and thus have potential to respond to both histamine and non-histaminergic pruritogens such as CQ and BAM8-22. It is conceived that this sub-population of sensory neurons may serve as itch-specific sensory neurons. A recent study by Han et al. further supported this idea [34] . Using genetically-labeled mice, they found that MrgprA3-expressing sensory responded to multiple pruritogens. Once these MrgprA3-positive neurons were genetically ablated, the mice showed severe impairment in the itch response against various pruritogens whereas pain sensitivity remained intact [34] . More interestingly, in TRPV1 knockin mice expressing TRPV1 only on MrgprA3-positive sensory neurons, capsaicin treatment induced itch but not pain response. These data confirm that MrgprA3-positive sensory neurons are indeed specifically dedicated to itch transmission, which supports a labeled-line theory.
What is intriguing is that those itch-transmitting neurons also express TRPV1, which are considered to be expressed in pain-transmitting neurons. In addition, pruriceptors utilize the same TRP channels as nociceptors to transduce itch signal; histaminergic neurons utilize TRPV1 and non-histaminergic neurons utilize TRPA1. Thus, TRPV1/TRPA1-activating noxious stimuli can potentially activate these pruriceptors. Then, how can one differentiate itch from pain signals transduced by these pruritogen-responsive neurons? Studies to date suggest a model in that the sepruritogen-responsive TRPV1-positive sensory neurons constitute itch-specific circuits and that this circuit is repressed by signals from pruritogen non-responsive nociceptors. Once pruritogen-responsive neurons are activated in the absence of a pain signal, it is perceived as an itch. In the condition that both pruriceptors and nociceptors are being activated, the signals delivered by pruriceptors are repressed by a signal from the nociceptors and thus the sensory stimulus is perceived as pain.
As for synaptic transmission by the itch-specific sensory neurons, gastrin-releasing peptide (GRP) was suggested as an itch-transmitting neurotransmitter [35, 36] . In this study, GRP was expressed in sensory neurons, while the GRP receptor (GRPR) was expressed in dorsal horn neurons. Intrathecal GRP administration elicited severe itch responses. In this study, both GRPR deletion and pharmacological inhibition significantly attenuated the scratch response against various pruritogen stimuli. In addition, ablation of GRPR-expressing neurons in the spinal cord almost completely abolished the scratch response against histaminergic as well as non-histaminergic pruritogens (CQ, PAR2 agonist, endothelin-1) [36] . Based on these studies, it has been argued that GRPR-positive dorsal horn neurons are itch-transmitting, second-order neurons. However, it was later argued that GRP is also expressed in natriuretic polypeptide b (Nppb) receptor-positive spinal cord dorsal horn neurons [37] . Ablation of these neurons does not affect the GRP-induced itch behavior, suggesting that GRP is actually a downstream mediator of Nppb receptor (NppbR)-positive neurons. Nppb is expressed and released from TRPV1/MrgprA3-positive DRG sensory neurons [37] . Collectively, these data suggest that Nppb is the neurotransmitter utilized by the itch specific sensory neurons. Nppb released from pruriceptors stimulate NppbR spinal cord neurons and then NppbR neurons release GRP in the spinal cord to activate GRPR-positive itch transmitting neurons.
Sensitization and regulatory mechanisms of itch and pain
Spontaneous pain, hyperalgesia, and allodynia are often detected in chronic pain patients. Likewise, chronic itch is associated with spontaneous itch, hyperknesis and alloknesis. These pathological pain and itch can be caused by sensitization of the normal pain and itch sensory system. The sensitization can be caused by alterations in both peripheral sensory nerves (peripheral sensitization) and the CNS neurons (central sensitization). Peripheral sensitization of pain and itch is often detected in inflammatory conditions. Various inflammatory mediators are reported to sensitize nociceptors. These include nerve growth factor (NGF), proinflammatory cytokines and chemokines, bradykinin, prostaglandin, ATP and others [4] . Nociceptors express one or more receptors for these inflammatory mediators and upon activation, the downstream intracellular signals from these receptors enhance the excitability of the nociceptors and thereby increase sensitivity to pain. Regulation of TRPV1 activity by phosphorylation is one of the underlying mechanisms for hypersensitivity to inflammatory pain. For example, NGF secreted during inflammatory conditions induces phosphorylation of TRPV1 and regulates membrane expression of this channel [38] . Prostaglandin E2 contributes to peripheral sensitization by inhibiting desensitization of TRPV1, which is mediated by AKAP150/PKA-dependent TRPV1 phosphorylation [39] . Similar mechanisms have been employed in the peripheral sensitization of itch. Increased excitability of pruriceptors is attributed to the peripheral itch sensitization. Upregulation of pruritogen receptor expression in sensory neurons is one of the underlying mechanisms [40, 41] . In the dry skin animal model of chronic itch, increased expressions of MrgprA3 and PAR2 have been detected in the skin-innervating sensory neurons [42] . Increased innervation of pruritic sensory neurons by sprouting has been also implicated. [41] .
Sensitization of pain and itch can also occur at the spinal cord level. For central sensitization of pain mechanisms, enhancement of excitatory glutamatergic neurotransmission and inhibition of inhibitory interneuronal input at the spinal cord dorsal horn have been implicated. Under normal conditions, AMPA and kainate receptors are involved in excitatory neurotransmissions at the dorsal horn. However, in chronic pain conditions, enhanced and consistent input of noxious signals to post-synaptic neurons recruit NMDA receptors, thereby enhancing synaptic transmission. This is reminiscent of the mechanisms of hippocampal long-term potentiation (LTP). In the hippocampus, recruitment of NMDA glutamate receptors in post-synaptic neurons contributes to the long-term potentiation of synaptic transmission [43] .
On the other hand, decreased tonic inhibition may also contribute to enhanced pain transmission. Pain projection neurons in the spinal cord dorsal horn are under the control of interneuron that deliver inhibitory input to post-synaptic neurons, which is the underlying mechanism of gate-control theory [44] . It has been identified that in chronic pain conditions due to nerve injury, these inhibitory inputs are decreased [45] . The decrease in the inhibitory input is possibly due to the demise or dysfunction of these inhibitory interneurons [45, 46] . Alternatively, changes in the characteristics of pain-projection neurons may be involved [47, 48] . In these studies, K + -Cl --cotransporter (KCC2) expression was decreased in the pain-projection neurons due to nerve injury. This resulted in an increase in intracellular Cl -concentration, thereby causing the synaptic input from GABAergic inhibitory interneurons that open chloride channels to fail to inhibit and instead depolarize the projection neurons. This enhances excitability and increases pain transmission.
Recently, glia-neuron communication has emerged as a novel mechanism underlying the central sensitization of pain. In nerve injury-induced chronic pain conditions, spinal cord microglia as well as astrocytes cells are activated. Inhibition of microglia and astrocytes activation by chemical inhibitors such as minocycline and fluorocitrate, respectively, attenuate nerve injury-induced neuropathic pain [49, 50] . It has been shown that proinflammatory mediators released from the activated microglia can sensitize and facilitate pain transmission. One of the underlying mechanisms involves BDNF from activated microglia down-regulating KCC2 in spinal cord neurons [48] . In addition, proinflammatory cytokines such as TNF-α, IL-1β, as well as nitric oxide (NO) contribute to the sensitization of the pain transmission. It has been proposed that ATP may trigger spinal cord microglia activation in the nerve injury-induced neuropathic pain [51] . In line with this finding, it has been suggested that several ATP receptors including P2X4 and P2X7 may be microglia-activating receptors after nerve injury [51, 52] . However, the expression of these receptors on the resting microglia in vivo has not been formally demonstrated. Therefore, the mechanisms of spinal cord microglia activation after nerve injury still need to be elucidated.
Comparable to pain-transmitting STT neurons, the itch projection neurons are also regulated by excitatory and inhibitory interneurons. In testicular orphan nuclear receptor 4 (TR4) conditional knockout mice in which excitatory spinal cord interneurons are depleted, there are reduced itch signal projections to the brain [53] . Studies indicate that there are distinct interneuron populations regulating pain versus itch projection neurons. The existence of itch-specific inhibitory interneurons has dramatically been demonstrated in the conditional knockout of Bhlhb5, a transcription factor gene involved in interneuron development. Characterization of these mice have proven that the deletion of bhlhb5-positive inhibitory interneurons in the spinal cord caused disinhibition of the itch neural circuit at the spinal cord level and spontaneous itch signal transmission [54] . However, pain transmission in these mice is not altered. These studies support the idea that central sensitization of itch can be also caused by alteration of inhibitory input at the spinal cord level. In addition, upregulation of an itch-transmitting neurotransmitter and its receptor such as GRP and GRPR, respectively, in the spinal cord may result in the enhancement of itch transmission in chronic itch. [55] . This central sensitization affects not only the intensity of the itch signal. In certain pathological conditions, it may also modulate the modality of the sensation. It has been observed that in lesioned areas of atopic dermatitis patients, nociceptive stimuli such as bradykinin treatment or electrical stimuli are perceived as itching and not as pain [56, 57] .
It is well known that itch and pain often contradict each other. For example, noxious stimuli to the periphery of a pruritic site alleviate ongoing itch sensations. Thus the pain signal seems to diminish the itch sensation. This might be one of the itch-relieving mechanisms of the scratch response. In contrast, a reduction in the pain signal often accompanies an itch sensation, which is most dramatically observed in the pruritogenic effect of prolonged morphine treatment to patients. In this case, inhibition of pain by the µ-opiate receptor often accompanies an induction of the itch signal [58] . Conversely, µ-opiate receptor antagonists suppress itch. In certain types of chronic pain conditions, pruritogen treatment induces pain instead of itch [59] . The counter-regulation between itch and pain seems to occur at the spinal cord level, according to a study by Liu et al. [60] . They developed conditional knockout mice in which the vesicular glutamate transporter (Vglut) 2 gene, which is required for the glutamate synaptic transmission, is deleted in primary nociceptors. In these mice, pain behaviors were severely compromised. In contrast, itch behavior was greatly enhanced in these mice. Furthermore, capsaicin injection into these mice no longer induced pain behaviors but induced scratch behaviors. These data imply that pain signal-transmitting synaptic glutamate release from nociceptors somehow suppresses itch signal transmission.
Toll-like receptors in pain and itch
TLRs are transmembrane glycoproteins involved in the innate immune responses. There are 13 members of the TLRs in the mammalian system. On the innate immune cells, TLRs detect microorganisms infection by recognizing their pathogen-associated molecular patterns [61] . Upon activation, TLRs trigger inflammatory signal in the innate immune cells leading to an innate immune response. Besides, TLRs can be activated by tissue damage-associated endogenous molecules, thereby functioning as receptors that monitor and sense tissue damage. Due to their canonical functions in immune and inflammatory responses, little attention has been paid to their role in sensory transmission. However, recent studies on the molecular mechanisms of pain and itch have uncovered unexpected roles of TLRs in the sensitization of pain and itch.
It was first reported that TLR4 expression plays an important role in nerve injury-induced neuropathic pain by Tanga et al. [8] . In this study, pain hypersensitivity and spinal cord microglia activation after L5 nerve transection was mitigated in TLR4 knockout mice. They suggested that TLR4 expressed on spinal cord cells contribute to the pain central sensitization. Our group also has reported that nerve injury-induced pain hyper-sensitivity and spinal cord microglia activation are attenuated in TLR2 knockout mice [62] . Spinal cord microglia activation is one of the key mechanisms of nerve injury-induced central sensitization of pain. In the spinal cord, microglia constitutively express TLR2 and 4 [63, 64] . Therefore, it is most likely that microglial TLR2 and 4 function as receptors for nerve injury-induced microglia activation, which in turn leads to the central sensitization of pain.
TLRs are also involved in the itch sensation. Liu et al., first reported that TLR3 is involved in itch sensitization. They found that TLR3 is expressed mainly in small-sized TRPV1-expressing neurons. The activation of these neuronal TLR3 by poly(IC) treatment directly excites sensory neurons and induces a scratch response [65] , suggesting that these TLR3/TRPV1-positive neurons are pruriceptors. In addition, scratch responses against histaminergic as well as non-histaminergic pruritogens are also severely impaired in these TLR3 knockout mice, althoughTLR3 is not required for pruritogen-induced itch signal transduction in the sensory neurons. Rather, TLR3 contributes to synaptic transmission of the itch signal and central sensitization at the spinal cord level. Recently, we also have reported a role of TLR4 in itch signal transmission [66] . We have found that histamine-and chloroquine-induced scratch responses are severely compromised in TLR4 knockout mice, suggesting that TLR4 is required for optimal itch signal transmission stimulated by these pruritogens. Of interest, TLR3 and 4 regulate itch with distinct mechanisms. While TLR3 contributes to the central sensitization of itch, TLR4 seems to mainly contribute to peripheral sensitization. TLR4 expression in sensory neurons facilitates itch signal transduction by enhancing TRPV1 activity. In addition, TLR4 expression is not limited to small-sized TRPV1-positive neurons but is also detected in large-sized neurons. Thus, unlike TLR3, TLR4 expression is not limited to itch-specific sensory neurons. Nonetheless, the sub-population of TRPV1 + neurons that co-express TLR4 is likely to mainly contribute to histamine-induced itch signal transduction.
Besides TLR3 and 4, TLR7 was also implicated in itch signal transmission. In a study by Liu et al., imiquimod, a synthetic TLR7 agonist, has been found to trigger action potentials in TLR7-expressing sensory neurons and induce an itch-specific response in mice [67] . However, in our study, pruritogenic effects of imiquimod were TLR7-independent, but rather acted on IP3R and potassium channels [68] [69] [70] . Therefore, the role of TLR7 in itch signal transduction or transmission is currently controversial.
Conclusions
Recent studies on itch and pain mechanisms over the last decade have greatly advanced our knowledge in this field. It is now clear that there is a distinct population of sensory neurons that are equipped with several pruritogen receptors and are dedicated to itch signal transduction. Likewise, distinct populations of STT projection neurons are involved in the transmission of itch and pain. Sensory signals of itch and pain cross-talk with each other, and the regulatory mechanisms of itch and pain transmission at the spinal cord level are being uncovered. However, we are just beginning to understand the underlying mechanisms and it is far from complete elucidation. Cell-type specific gene modification techniques and recently developed optogenetic tools will be of important use to dissect the mechanisms and circuits of these sensory modalities in future studies. Chronic and exaggerated sensation of itch and pain such and neuropathic pain and itch are debilitating human diseases. Deciphering the molecular and cellular mechanisms of itch and pain sensitization will allow us to identify novel therapeutic targets and treat these devastating diseases.
